Solexa Q3 Revenues Fall 33 Percent as Company Shifts from MPSS to Sequencing | GenomeWeb
NEW YORK (GenomeWeb News) - Solexa today said third-quarter revenues decreased 33 percent as R&D spending rose 21 percent and its net loss decreased 8 percent.
 
Total receipts for the three months ended Sept. 30 fell to $569,000 from $844,000 in the third quarter of 2005. Solexa said all of its revenues are from its legacy MPSS technology, which the company has now discontinued, and do not include any contribution from its Genome Analysis System DNA sequencing technology. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.